Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies

Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials

(2022) John R. Ussher et al.   DIABETES

Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults

(2021) Elisabetta Patorno et al.   DIABETES CARE

Why Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both?

(2021) Alice Y.Y. Cheng   CIRCULATION

Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial

(2021) Ehtasham Ahmad et al.   DIABETES OBESITY & METABOLISM

Lower risk of death and cardiovascular events in patients with diabetes initiating GLP ‐1 receptor agonists or SGLT ‐2 inhibitors: a real‐world study on two Italian cohorts

(2021) Marta Baviera et al.   DIABETES OBESITY & METABOLISM

Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

(2021) Moa Lugner et al.   Cardiovascular Diabetology

Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials

(2021) Jonathan J. H. Bray et al.   DIABETES OBESITY & METABOLISM

Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies

(2021) Omar S. Alkhezi et al.   Primary Care Diabetes

Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors

(2021) Donna Shu-Han Lin et al.   DIABETOLOGIA

Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care

(2021) Stephan Jacob et al.   DRUGS

Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study

(2021) Christina E. DeRemer et al.   JOURNAL OF DIABETES AND ITS COMPLICATIONS

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes

(2021) Hertzel C. Gerstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study

(2021) Spela Zerovnik et al.   BMJ Open

Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study

(2021) Reimar W. Thomsen et al.   Journal of the American Heart Association

Cardiovascular Outcomes with GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Patients with Type 2 Diabetes

(2021) Caroline H Nørgaard et al.   European Heart Journal-Cardiovascular Pharmacotherapy

Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease

(2021) Elisabetta Patorno et al.   ANNALS OF INTERNAL MEDICINE

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

(2021) Naveed Sattar et al.   Lancet Diabetes & Endocrinology

Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon‐like peptide‐1 receptor agonists

(2020) Veronica Sciannameo et al.   DIABETES OBESITY & METABOLISM

Use of Glucagon-Like Peptide 1 Receptor Agonists and Risk of Serious Renal Events: Scandinavian Cohort Study

(2020) Björn Pasternak et al.   DIABETES CARE

Using RWE research to extend clinical trials in diabetes: An example with implications for the future

(2020) John D. Seeger et al.   DIABETES OBESITY & METABOLISM

Glucose control: not just a bystander in GLP-1RA-mediated cardiovascular protection

(2020) Irene Caruso et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study

(2020) Chun-Ting Yang et al.   Cardiovascular Diabetology

Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice

(2020) Enrico Longato et al.   Cardiovascular Diabetology

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life

(2020) Enrico Longato et al.   BMJ Open Diabetes Research & Care

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

(2020) Christopher P. Cannon et al.   NEW ENGLAND JOURNAL OF MEDICINE

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021

(2020)   DIABETES CARE

Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect

(2020) Dragana Nikolic et al.   Diabetes Therapy

Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings

(2019) B. Guerci et al.   DIABETES & METABOLISM

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

(2019) Hertzel C Gerstein et al.   LANCET

Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial

(2019) Christian Anholm et al.   ATHEROSCLEROSIS

Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials

(2019) Irene Caruso et al.   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure

(2019) Francesco Giorgino et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement

(2018) Francesco Giorgino et al.   Patient Preference and Adherence

Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population

(2018) Kristina S. Boye et al.   Diabetes Therapy

Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population

(2018) Kristina S. Boye et al.   Diabetes Therapy

Effects of Dulaglutide and Insulin Glargine on Estimated Glomerular Filtration Rate in a Real-world Setting

(2018) Kristina S. Boye et al.   CLINICAL THERAPEUTICS

The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial

(2018) Ketan Dhatariya et al.   DIABETES CARE

Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort

(2018) Marco Mirani et al.   PHARMACOLOGICAL RESEARCH

Clinical Impact of 5 Years of Liraglutide Treatment on Cardiovascular Risk Factors in Patients with Type 2 Diabetes Mellitus in a Real-Life Setting in Italy: An Observational Study

(2018) Vera Frison et al.   Diabetes Therapy

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations

(2018) Peter G. M. Mol et al.   DIABETES OBESITY & METABOLISM

Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study

(2018) Peter Ueda et al.   BMJ-British Medical Journal

Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden

(2018) Henrik Svanström et al.   Lancet Diabetes & Endocrinology

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study

(2017) Alessandro Ciresi et al.   Diabetes Therapy

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study

(2017) Alessandro Ciresi et al.   Diabetes Therapy

Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study

(2016) Manfredi Rizzo et al.   Cardiovascular Diabetology

Comparative cardiovascular safety of glucagon-like peptide-1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study

(2016) E. Patorno et al.   DIABETES OBESITY & METABOLISM

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

(2009) D. I. Brixner et al.   DIABETES OBESITY & METABOLISM